Breast
cancer is the most common form of cancer among women and second most common
cause of cancer death in women across the world, because one third of women
with breast cancer die from breast cancer.The strongest risk factors for
developing this cancer include being female (only 1% of cases are diagnosed in
males) and also increasing age. Women
who have a first-degree relative (a mother or sister) who have developed breast
cancer are at an increased risk themselves of developing the disease. The degree of this risk is affected by the
age of her relative at diagnosis. If the
relative was pre - menopausal at the time of diagnosis, then her own risk is
greatest. Immunotherapy might help in it.
The
risk of this cancer also corresponds to exposure to both endogenous and
exogenous estrogen. The longer the
menstrual history the greater the risk.
Both early menarche and late menopause are associated with an increased
risk of breast cancer. Females who begin
menstruation at the age of 12 or younger are at greater risk than those who
begin after the age of 14. The risk for women
who undergo menopause prior to the age of 45 is about half that of women who
undergo menopause after the age of 55.
 |
| www.gapsos.com |
Pregnancy
has alternating impacts on the risk of this cancer. Those women who have their
first pregnancy after the age of 30 have a greater risk of breast cancer than
those who have children at a younger age.
There
is an increased risk of this cancer associated with the use of exogenous
estrogen, such as in hormone replacement therapy (HRT). Women taking long term estrogens have a 30%
increase in the risk of breast cancer, despite the cardiovascular benefits
associated with this therapy.
There
has been an increased risk of this cancer found in women currently taking oral
contraceptives. This risk appears to be
with long-term use, and returns to normal when the oral contraceptives are
stopped.
Various
immunotherapeutic cancer agents are developed by using new technologies to
treat this cancer. Lapatinib (kinase
inhibitor) and Pertuzumab (monoclonal antibody drug) have received approval
by the Food and Drug Administration (FDA) for the treatment of this cancer,
while MEDI0680, and Bevacizumab(monoclonal antibody drugs), Gene Modified T
Cells and Interleukin 2 (adoptive T cell therapy) are under evaluation of
clinical trial for FDA approval.
For
more information kindly contact us at www.gapsos.com
No comments:
Post a Comment